Francesco Caiazza

Francesco Caiazza

Auto-generated profile, based on publicly available information

Francesco Caiazza

UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2015 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
FCFrancesco Caiazza
Francesco Caiazza
ERElizabeth Ryan
Elizabeth Ryan
GDGlen Doherty
Glen Doherty
DWDesmond C. Winter
Desmond C. Winter
KSKieran Sheahan
Kieran Sheahan
Upon binding their cognate receptors, ERα (ESR1) and ERβ (ESR2), estrogens activate intracellular signaling cascades that have important consequences for cellular behavior. Historically linked to carcinogenesis in reproductive organs, estrogens have also been implicated in the pathogenesis of different cancer types of non-reproductive tissues including the colon. ERβ is the predominant estrogen receptor expressed in both normal and malignant colonic epithelium. However, during colon cancer progression ERβ expression is lost, suggesting estrogen signaling may play a role in disease progression. Estrogens may in fact exert an anti-tumor effect through selective activation of pro-apoptotic signaling mediated by ERβ, inhibition of inflammatory signals and modulation of the tumor microenvironment. In this review we analyze the estrogen pathway as a possible therapeutic avenue in colorectal cancer, we report the most recent experimental evidence to explain the cellular and molecular mechanisms of estrogen-mediated protection against colorectal tumorigenesis, and we discuss future challenges and potential avenues for targeted therapy.

1 March 2007 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
PGPaola Galluzzo
Paola Galluzzo
FCFrancesco Caiazza
Francesco Caiazza
Sandra MorenoSandra Moreno
Sandra Moreno
MMMaria Marino
Maria Marino
The cellular functions regulated by 17β-estradiol (E2) start after the hormone binds to its receptors (i.e., ERα and ERβ ). These act as ligand-dependent transcription factor transactivating target genes. In addition, E2 induces non-genomic actions, whose activation is triggered by a fraction of the ERs localized at the plasma membrane. Palmitoylation allows ERα to localize at the plasma membrane, to associate with caveolin-1, and, upon E2 stimulation, to activate rapid signals relevant for cell proliferation. The existence of a mechanism, which allows ERβ localization at the plasma membrane and its putative role in anti-proliferative E2 effects is completely unknown. Here, the susceptibility of ERβ to undergo palmitoylation and the role played by this process has been analyzed in DLD-1 containing endogenous ERβ or in HeLa cells transiently transfected with ERβ or ERα expression vectors. As for ERα , palmitoylation is necessary for ERβ localization at the plasma membrane and its association with caveolin-1 but, in contrast to ERα , the E2 binding increases ERβ association with caveolin-1 and the p38 member of MAPK family. Moreover, the palmitoyl acyl transferase (PAT) inhibitor blocks the ability of ERβ –E2 complex to activate p38 impairing the receptor-dependent activation of downstream proapoptotic cascade (i.e., caspase-3 activation and poly(ADP-ribose)polymerase (PARP) cleavage). Consequently, palmitoylation must be considered to be a molecular device for ERβ , which allows these receptors to interact with the plasma membrane and to regulate E2-induced non-genomic functions relevant to the anti-proliferative effect of this hormone.

1 January 2013 in Frontiers in Bioscience-Scholar
Verified
Journal Article
Closed access
ASAritro Sen
Aritro Sen
FCFrancesco Caiazza
Francesco Caiazza
The release of a mature healthy egg for fertilization is the center of the entire reproductive process. From the time of embryonic development till fertilization, the oocyte undergoes several stop-and-go periods. In most animals, oocytes are held in meiotic arrest in prophase I prior to ovulation. The ovulatory luteinizing hormone (LH) surge promotes the resumption of meiosis of the arrested oocytes and their progression through the second meiotic cycle, only to be arrested again at metaphase II until fertilization. This review addresses the underlying mechanisms involved in maintaining the oocyte in meiotic arrest as well as the signaling pathways responsible for releasing it from the arrested phase just prior to ovulation until the completion of meiosis at the time of fertilization.

11 September 2012 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
PMP. M. McGowan
P. M. McGowan
MMMaeve Mullooly
Maeve Mullooly
FCF. Caiazza
F. Caiazza
SSS. Sukor
S. Sukor
SMStephen Madden
Stephen Madden
MDM. J. Duffy
M. J. Duffy
Validated targeted therapy is currently unavailable for patients with invasive breast cancer negative for oestrogen receptors, progesterone receptors and HER2 [i.e., those with triple-negative (TN) disease]. ADAM-17 is a protease involved in the activations of several ligands that bind to and promotes intracellular signalling from the EGFR/HER family of receptors. Expression of ADAM-17 was measured in 86 triple-negative and 96 non-triple-negative breast cancers. The ADAM-17 specific inhibitor, PF-5480090 (TMI-002, Pfizer) was tested in a panel of breast cancer cell lines for effects on functional outputs. In this study we show using both Western blotting and immunohistochemistry that ADAM-17 is expressed at significantly higher levels in TN than non-TN breast cancers. Using a panel of breast cancer cell lines in culture, PF-5480090 was found to decrease release of the EGFR ligand, TGF-alpha, decrease levels of phosphorylated EGFR and block cell proliferation in a cell-type-dependent manner. Potentially important was the finding of a significant and moderately strong correlation between ADAM-17 activity and extent of proliferation inhibition by PF-5480090 (r = 0.809; p = 0.003; n = 11). Pretreatment of cell lines with PF-5480090 enhanced response to several different cytotoxic and anti-EGFR/HER agents. It is concluded that inhibition of ADAM-17, especially in combination with chemotherapy or anti-EGFR/HER inhibitors, may be a new approach for treating breast cancer, including patients with TN disease.

28 November 2017 in eLife
Verified
Journal Article
Open access
MWMichael B Winter
Michael B Winter
FGFlorencia La Greca
Florencia La Greca
SAShirin Arastu-Kapur
Shirin Arastu-Kapur
FCFrancesco Caiazza
Francesco Caiazza
PCPeter Cimermancic
Peter Cimermancic
CCCharles Craik
Charles Craik
The immunoproteasome (iP) has been proposed to perform specialized roles in MHC class I antigen presentation, cytokine modulation, and T cell differentiation and has emerged as a promising therapeutic target for autoimmune disorders and cancer. However, divergence in function between the iP and the constitutive proteasome (cP) has been unclear. A global peptide library-based screening strategy revealed that the proteasomes have overlapping but distinct substrate specificities. Differing iP specificity alters the quantity of production of certain MHC I epitopes but does not appear to be preferentially suited for antigen presentation. Furthermore, iP specificity was found to have likely arisen through genetic drift from the ancestral cP. Specificity differences were exploited to develop isoform-selective substrates. Cellular profiling using these substrates revealed that divergence in regulation of the iP balances its relative contribution to proteasome capacity in immune cells, resulting in selective recovery from inhibition. These findings have implications for iP-targeted therapeutic development.

1 July 2007 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
FCFrancesco Caiazza
Francesco Caiazza
PGPaola Galluzzo
Paola Galluzzo
SLStefano Lorenzetti
Stefano Lorenzetti
MMMaria Marino
Maria Marino